• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Shire

Takeda reaches $62B deal to buy Shire

May 8, 2018 By Sarah Faulkner

Takeda, Shire

After a series of offers, Takeda (TYO:4502) said today that it reached an agreement with Shire (NSDQ:SHPG) to acquire the U.S.-based company in a deal valued at $62 billion. The merger was approved by both companies’ boards of directors, according to Takeda, and is slated to close in the first half of 2019. Takeda investors are wary […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Shire, Takeda Pharmaceutical Co

Shire accepts $64B takeover bid from Takeda

April 25, 2018 By Fink Densford

Takeda, Shire

Shire (NSDQ:SHPG) said late yesterday it agreed to Takeda Pharmaceutical‘s (TYO:4502) reworked acquisition bid, now worth approximately $64.2 billion (GBP £46 billion). The takeover offer will now go to Shire’s shareholders for approval, having received backing from Dublin, Ireland-based Shire’s board of directors, according to a press release. In the deal, Takeda will offer approximately 0.839 […]

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Shire, Takeda Pharmaceutical Co

Report: Takeda raises $60B offer for Shire, nears prelim acquisition agreement

April 24, 2018 By Fink Densford

Takeda, Shire

Takeda Pharmaceutical (TYO:4502) has sweetened its approximately $60 billion bid for Shire (NSDQ:SHPG) and is approaching a preliminary agreement for acquisition, according to a new report from Bloomberg. The deal could come to a head as early as today, according to the report, as both companies have been working on a tentative agreement and price for the […]

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Pharmaceuticals Tagged With: Allergan, Shire, Takeda Pharmaceutical Co

Update: Allergan, Takeda spar for Shire

April 19, 2018 By Brad Perriello

Allergan, Takeda spar for Spire

Hours after Allergan (NYSE:AGN) said it was considering an acquisition of Shire (NSDQ:SHPG), the Dublin-based company announced that it does not intend to make such an offer. Reports also surfaced today that Shire rejected a $63 billion takeover offer from Takeda Pharmaceutical (TYO:4502). Reuters, which first broke the news of Allergan’s interest in Shire, citing a pair of unnamed sources, […]

Filed Under: Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: Allergan, Shire, Takeda Pharmaceutical Co

Ex-Advanced BioHealing exec draws probation in VA fraud case

February 12, 2018 By Brad Perriello

Advanced BioHealing

A former Advanced BioHealing executive who admitted to federal charges that he bribed U.S. Veterans Affairs Dept. doctors to use the company’s DermaGraft biologic wound dressing last week drew probation in the case. Federal had prosecutors accused Todd Clawson, who left the company in 2012, of participating in a scheme to bribe VA physicians to use the DermaGraft diabetic […]

Filed Under: Featured, Legal News, Regenerative Medicine, Wound Care Tagged With: Advanced BioHealing, Shire

Rani Therapeutics nabs $53m for robotic pill injection tech

February 8, 2018 By Sarah Faulkner

Rani Therapeutics

Rani Therapeutics has raised $53 million to support manufacturing as it gears up for clinical trials of its robotic pill technology. New investors like GeneScience Pharmaceuticals and Shire (NSDQ:SHPG) joined existing investors like Alphabet’s GV, Novartis (NYSE:NVS) and AstraZeneca (NYSE:AZN). Rani Therapeutics, an InCube Lab spin-out started in 2012, has developed a capsule that delivers an intestinal injection […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: Allergan, AstraZeneca plc, Novartis, ranitherapeutics, Shire

How this biotech plans to go up against big pharma with its eye disease products

December 29, 2017 By Sarah Faulkner

Ocugen

Shankar Musunuri has spent time in both the pharmaceutical world and the biotech arena – after 15 years at Pfizer (NYSE:PFE), he went on to launch several biotech start-ups. As co-founder, chairman & chief executive of Ocugen, he is looking to bring eye disease products to the patients that big pharma’s drugs have left out. “There’s […]

Filed Under: Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Massachusetts Eye & Ear Infirmary, ocugen, Pfizer Inc., Regeneron, Roche, Shire

Shire taps Rani Therapeutics’ oral delivery tech for hemophilia therapy

December 14, 2017 By Sarah Faulkner

Shire

Shire (NSDQ:SHPG) said this week that it is collaborating with Rani Therapeutics to combine the company’s Rani Pill technology for the delivery of factor VIII therapy in patients with hemophilia A. According to the terms of the deal, Shire has the exclusive option to negotiate a license to develop and commercialize the technology as a delivery […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: ranitherapeutics, Shire

BioDelivery Sciences president, CEO Sirgo to retire | Personnel Moves – Aug 29, 2017

August 29, 2017 By Sarah Faulkner

BioDelivery Sciences International

BioDelivery Sciences (NSDQ:BDSI) said last week that its president & CEO, Mark Sirgo, plans to retire at the end of this year. Sirgo has held the corner office at the Raleigh, N.C.-based company since 2005. He will stay on as vice chairman of the board and will help determine his successor, BioDelivery Sciences reported. “After thirteen […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, BioDelivery Sciences International, Insulet, Merrimack Pharmaceuticals, Novartis, Ocular Therapeutix, pierispharmaceuticals, Proteus Digital Health, Shire, SteadyMed Therapeutics

Another extended-release ADHD drug wins FDA nod

June 21, 2017 By Sarah Faulkner

Shire

Days after Neos Therapeutics (NSDQ:NEOS) nabbed U.S. regulatory approval for its controlled-release formulation of methylphenidate, Shire (NSDQ:SHPG) said it won a nod from the FDA for its long-acting ADHD drug. The drug, Mydayis, is made up of the same active ingredient in Shire’s ADHD treatment Adderall XR – amphetamine – but it is designed to last up to […]

Filed Under: Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: neostherapeutics, Shire

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS